{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Biomerica, Inc.
Biomerica, Inc. Hits New 52-Week Low at $1.60 Amid Declining Sales
Biomerica, Inc. has reached a new 52-week low, reflecting a difficult year marked by a significant stock price decline. The company faces ongoing financial challenges, including negative return on equity, a high debt-to-equity ratio, and decreasing net sales, alongside reduced institutional investor participation.
Biomerica, Inc. Hits New 52-Week Low at $1.61 Amid Declining Sales
Biomerica, Inc. has reached a new 52-week low, reflecting a challenging year marked by a significant stock price decline. The company faces ongoing financial difficulties, including negative return on equity and a decrease in net sales. Institutional investor participation has also diminished, indicating concerns about its growth prospects.
Biomerica, Inc. Hits New 52-Week Low at $1.63 Amidst Declining Performance
Biomerica, Inc. has reached a new 52-week low, reflecting a challenging year marked by a significant stock price decline. The company faces ongoing financial difficulties, including negative return on equity, a high debt-to-equity ratio, and decreasing net sales. Institutional investor participation has also diminished recently.
Biomerica, Inc. Stock Plummets to New 52-Week Low of $1.73
Biomerica, Inc. has reached a new 52-week low, reflecting a challenging year marked by a significant stock price decline. The company faces financial difficulties, including negative return on equity and decreasing net sales. Institutional investor participation has also decreased, indicating ongoing challenges in the competitive Pharmaceuticals & Biotechnology sector.
Biomerica, Inc. Stock Plummets to New 52-Week Low of $1.76
Biomerica, Inc. has reached a new 52-week low, reflecting a difficult year marked by a significant stock price decline. The company faces ongoing financial challenges, including negative return on equity and declining net sales. Institutional investor participation has also decreased, raising concerns about its financial health and growth prospects.
Biomerica, Inc. Hits New 52-Week Low at $1.79 Amid Declining Sales
Biomerica, Inc. has reached a new 52-week low, reflecting a challenging year marked by a significant decline in performance and a small market capitalization of approximately USD 6 million. The company faces ongoing financial difficulties, including negative return on equity and declining net sales, alongside reduced institutional investor participation.
Is Biomerica, Inc. technically bullish or bearish?
As of August 26, 2025, Biomerica, Inc. is in a mildly bearish trend, with bearish signals from the weekly MACD and Bollinger Bands, despite some mildly bullish indicators, and it has underperformed the S&P 500 recently while outperforming it year-to-date and over the past year.
Is Biomerica, Inc. technically bullish or bearish?
As of June 13, 2025, Biomerica, Inc. has shifted from mildly bullish to mildly bearish, influenced by bearish signals from the weekly MACD, Bollinger Bands, and moving averages, despite mixed monthly indicators.
Who are in the management team of Biomerica, Inc.?
As of March 2022, the management team of Biomerica, Inc. includes CEO Zackary Irani, Lead Independent Executive Vice Chairman Allen Barbieri, and Independent Directors Francis Cano, Catherine Coste, Jane Emerson, and Mark Sirgo, who oversee the company's operations and strategy.
What does Biomerica, Inc. do?
Biomerica, Inc. is a biomedical company that develops and markets medical diagnostic products for chronic diseases. As of February 2025, it has a market cap of $8.30 million, with net sales of $1 million and a net profit of -$1 million.
How big is Biomerica, Inc.?
As of Jun 18, Biomerica, Inc. has a market capitalization of 8.30 million, with net sales of 5.69 million and a net profit of -4.85 million over the latest four quarters. The company reported shareholder's funds of 6.59 million and total assets of 9.25 million as of May 24.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
